Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Larimar Therapeutics, Inc. - Common Stock (NQ:LRMR)

3.690 -0.120 (-3.15%)
Streaming Delayed Price Updated: 9:41 AM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Larimar Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
What's going on in today's after hours session ↗
As the regular session of the US market on Monday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment. 
Via Chartmill
News headline image
Rosen Law Firm Encourages Larimar Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – LRMR
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
LRMR Investors Have Opportunity to Join Larimar Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
From Schall Law
Via GlobeNewswire
Larimar Therapeutics Stock Slumps Pre-market Over High Anaphylaxis Rate In Drug Study ↗
Via Stocktwits
News headline image
The Best AI for Picking Stocks, Ranked by Performance ↗
AI can pick stocks, but that doesn't mean it will do a good job. Here's a look at how the choices made by 7 leading AIs performed over a 90-day time period. 
Via MarketBeat
Topics Artificial Intelligence ETFs
News headline image
Rosen Law Firm Encourages Larimar Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – LRMR
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
Larimar Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – LRMR
From DJS Law Group
Via Business Wire
News headline image
LRMR Investors Have Opportunity to Join Larimar Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
Quantum Computing, Mesoblast And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Which stocks are moving on Wednesday? ↗
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
News headline image
Let's take a look at the stocks that are in motion in today's session. ↗
Intrigued by the market activity one hour before the close of the markets on Monday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Gainers cbdMD (AMEX:YCBD) shares rose 116.3% to $1.35 during Monday's regular session. The company's market cap stands at $5.5 million. Zura Bio (NASDAQ: ZURA) stock moved upwards by 42.94% to $3.44.... 
Via Benzinga
News headline image
Top stock movements in today's session. ↗
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements. 
Via Chartmill
News headline image
Larimar Therapeutics Stock Falls After Patients Report Allergic Reaction In Pivotal Study ↗
Larimar Therapeutics Inc. (NASDAQ: LRMR) is trading lower on Monday after the company released data from the ongoing long-term open-label (OL) study evaluating daily subcutaneous 25 mg and 50 mg... 
Via Benzinga
News headline image
There are notable gap-ups and gap-downs in today's session. ↗
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Monday. Let's explore the market movements and identify the stocks with significant gaps. 
Via Chartmill
News headline image
Wondering what's happening in today's pre-market session? ↗
Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Gainers Dogwood Therapeutics (NASDAQ: DWTX) stock moved upwards by 80.1% to $9.94 during Monday's pre-market session. The market value of their outstanding shares is at $10.5 million. 
Via Benzinga
News headline image
Why Merus Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket ↗
Shares of Merus NV (NASDAQ: MRUS) rose sharply in today's pre-market trading. Genmab announced plans to acquire Merus for $8 billion in all-cash deal adding breakthrough therapy Petosemtamab to its... 
Via Benzinga
News headline image
Larimar Beats Q2 Loss Estimates ↗
Via The Motley Fool
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
What's going on in today's after hours session ↗
Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session. 
Via Chartmill
News headline image
This MicroStrategy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗
 
Via Benzinga
News headline image
What's Going On With Larimar Therapeutics Stock On Tuesday? ↗
Larimar Therapeutics reports promising FXN level increases with 25 mg nomlabofusp, advancing towards dose escalation for Friedreich's Ataxia treatment. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Crude Oil Down 1%; Webuy Global Shares Spike Higher ↗
 
Via Benzinga
News headline image
Why Is Larimar Therapeutics Stock Trading Lower On Monday? ↗
Larimar Therapeutics shares long-term OLE study data on nomlabofusp, showing increased FXN levels in Friedreich's Ataxia patients and well-tolerated treatment. 
Via Benzinga
News headline image
Larimar Therapeutics' New Drug Could Transform Treatment For Rare Neurological Disease, Analyst Sees Over 200% Upside For Stock ↗
Oppenheimer has initiated coverage on Larimar Therapeutics, emphasizing its lead program Nomlabofusp as a transformative therapy for Friedreich's ataxia. With a price target of $26, the company plans... 
Via Benzinga
News headline image
G-III Apparel Posts Upbeat Results, Joins NIO, Yext, Shoe Carnival And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.